This article is from the source 'rtcom' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.
You can find the current article at its original source at https://www.rt.com/news/526873-ema-no-covid-vaccine-efficacy-threshold/
The article has changed 3 times. There is an RSS feed of changes available.
| Version 1 | Version 2 |
|---|---|
| EU drugs regulator says it won’t impose 50% efficacy threshold for Covid-19 vaccines after disappointing result in CureVac trial | EU drugs regulator says it won’t impose 50% efficacy threshold for Covid-19 vaccines after disappointing result in CureVac trial |
| (about 2 months later) | |
| The European Medicines Agency (EMA) has said it will not bring in a minimum efficacy threshold for Covid-19 vaccines. The comment comes after clinical trials showed Germany’s CureVac jab to be only 47% effective against the virus. | The European Medicines Agency (EMA) has said it will not bring in a minimum efficacy threshold for Covid-19 vaccines. The comment comes after clinical trials showed Germany’s CureVac jab to be only 47% effective against the virus. |
| CureVac announced data on the efficacy of its jab on Wednesday after it was tested in second- and third-phase trials involving 40,000 people across ten countries. | CureVac announced data on the efficacy of its jab on Wednesday after it was tested in second- and third-phase trials involving 40,000 people across ten countries. |
| The company suggested variants of the virus may be behind the poor result. | The company suggested variants of the virus may be behind the poor result. |
| On Thursday, the EMA’s vaccine chief Marco Cavaleri said it was “a bit early to say” after being asked by a journalist about the CureVac results and the threat variants may pose to vaccine efficacy. | On Thursday, the EMA’s vaccine chief Marco Cavaleri said it was “a bit early to say” after being asked by a journalist about the CureVac results and the threat variants may pose to vaccine efficacy. |
| “We will need to collect all the final data from this clinical trial, and have a good analysis of the outcome throughout different regions, age groups and according to different variants,” he told an EMA briefing. | “We will need to collect all the final data from this clinical trial, and have a good analysis of the outcome throughout different regions, age groups and according to different variants,” he told an EMA briefing. |
| Asked specifically about a 50% efficacy minimum level for vaccines, he added that the EMA had “always felt it was difficult to define upfront a threshold.” | Asked specifically about a 50% efficacy minimum level for vaccines, he added that the EMA had “always felt it was difficult to define upfront a threshold.” |
| Think your friends would be interested? Share this story! | Think your friends would be interested? Share this story! |